BCG 010
Alternative Names: BCG-010Latest Information Update: 14 Jun 2023
At a glance
- Originator Beijing Biocytogen
- Developer Beijing Biocytogen; Undisclosed
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action NK cell lectin-like receptor subfamily C antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer